Skip to content

Intraarticular Gold Microparticles for Hip Osteoarthritis

Intraarticular Gold Microparticles for Hip Osteoarthritis - a 2-year Follow-up Pilot Study.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06186115
Enrollment
20
Registered
2023-12-29
Start date
2024-03-04
Completion date
2024-05-01
Last updated
2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Hip

Keywords

Hip osteoarthritis, Intra articular gold, Outcome

Brief summary

In a pilot study, the investigators recently showed that intraarticular metallic gold microparticles reduce knee osteoarthritis pain for up to two years and found associated significant proteomic changes in serum and synovial fluid within eight weeks. This study aim to evaluate the outcome after intra-articular injection of gold microparticles for hip osteoarthritis.

Detailed description

A cohort of 20 patients, aged ≥ 18 years, with pain ≥ 3 months, and Kellgren-Lawrence OA grade 2-4, will beincluded. Metallic gold 20 mg, 72.000 pieces, 20-40 µ-meter (Berlock-Micro-Implants, HumanGoldInject) (1) were injected into the hip joint using hyaluronic acid as the carrier. In total, we treated 24 hip joints. The primary outcome was the Western Ontario and McMaster Universities Arthritis Index (WOMAC).

Interventions

COMBINATION_PRODUCTGold

Intra articular

Sponsors

Aalborg University Hospital
CollaboratorOTHER
Northern Orthopaedic Division, Denmark
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* confirmed moderate hip OA (Kellgren-Lawrence grade ≥ 2), pain for more than 3 months, and maximal pain intensity VAS (Visual Analogue Scale, 0-10) ≥ 5 during the last week

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
WOMAC2 yearWestern Ontario and McMaster Universities Arthritis Index, sub-scores for pain, stiffness, and function, containing 24 questions: 5 pain questions, two stiffness questions, and 17 physical function questions.

Secondary

MeasureTime frameDescription
PainDetect2 yearThe secondary outcome measure PainDetect questionnaire (PDQ) comprises three major components, gradation of pain, pain course pattern, and radiating pain. Seven questions evaluate the gradation of pain. The patient scored each question using a 0 to 5 score with 0 = never, 1 = hardly noticed, 2 = slightly, 3 = moderately, 4 = strongly and 5 = very strongly. There is one question evaluating pain course patterns. Patients select from one of four pictures indicating which pattern best describes their course of pain. Each picture has a unique score of 0, -1, or +1 (2 pictures have this score possible). One question evaluates radiating pain with a yes (score of +2) or no (score of 0) response option. PDQ is scored from 0 to 38, with total scores \< 13 considered to represent nociceptive pain, 13-18 possible neuropathic pain, and \> 18 representing neuropathic pain.

Countries

Denmark

Contacts

Primary ContactSten Rasmussen, MD PhD
sten@dcm.aau.dk+4525520462

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026